Prostatype Genomics (Sweden) Technical Analysis
| PROGEN Stock | SEK 1.94 0.04 2.11% |
As of the 2nd of February, Prostatype Genomics holds the Coefficient Of Variation of 560.81, risk adjusted performance of 0.1385, and Semi Deviation of 8.02. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Prostatype Genomics, as well as the relationship between them.
Prostatype Genomics Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Prostatype, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to ProstatypeProstatype |
Prostatype Genomics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Prostatype Genomics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Prostatype Genomics.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Prostatype Genomics on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Prostatype Genomics AB or generate 0.0% return on investment in Prostatype Genomics over 90 days. Prostatype Genomics is related to or competes with Qlife Holding, Aino Health, Fluicell, 2cureX AB, Chordate Medical, and Stayble Therapeutics. Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests More
Prostatype Genomics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Prostatype Genomics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Prostatype Genomics AB upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 9.53 | |||
| Information Ratio | 0.1752 | |||
| Maximum Drawdown | 74.84 | |||
| Value At Risk | (10.71) | |||
| Potential Upside | 30.0 |
Prostatype Genomics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Prostatype Genomics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Prostatype Genomics' standard deviation. In reality, there are many statistical measures that can use Prostatype Genomics historical prices to predict the future Prostatype Genomics' volatility.| Risk Adjusted Performance | 0.1385 | |||
| Jensen Alpha | 2.53 | |||
| Total Risk Alpha | 1.84 | |||
| Sortino Ratio | 0.261 | |||
| Treynor Ratio | (13.00) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Prostatype Genomics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Prostatype Genomics February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1385 | |||
| Market Risk Adjusted Performance | (12.99) | |||
| Mean Deviation | 8.88 | |||
| Semi Deviation | 8.02 | |||
| Downside Deviation | 9.53 | |||
| Coefficient Of Variation | 560.81 | |||
| Standard Deviation | 14.2 | |||
| Variance | 201.78 | |||
| Information Ratio | 0.1752 | |||
| Jensen Alpha | 2.53 | |||
| Total Risk Alpha | 1.84 | |||
| Sortino Ratio | 0.261 | |||
| Treynor Ratio | (13.00) | |||
| Maximum Drawdown | 74.84 | |||
| Value At Risk | (10.71) | |||
| Potential Upside | 30.0 | |||
| Downside Variance | 90.87 | |||
| Semi Variance | 64.24 | |||
| Expected Short fall | (12.09) | |||
| Skewness | 1.66 | |||
| Kurtosis | 6.17 |
Prostatype Genomics Backtested Returns
Prostatype Genomics is out of control given 3 months investment horizon. Prostatype Genomics maintains Sharpe Ratio (i.e., Efficiency) of 0.2, which implies the firm had a 0.2 % return per unit of risk over the last 3 months. We were able to break down and interpolate data for thirty different technical indicators, which can help you to evaluate if expected returns of 3.03% are justified by taking the suggested risk. Use Prostatype Genomics Semi Deviation of 8.02, coefficient of variation of 560.81, and Risk Adjusted Performance of 0.1385 to evaluate company specific risk that cannot be diversified away. Prostatype Genomics holds a performance score of 16 on a scale of zero to a hundred. The company holds a Beta of -0.19, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Prostatype Genomics are expected to decrease at a much lower rate. During the bear market, Prostatype Genomics is likely to outperform the market. Use Prostatype Genomics maximum drawdown, accumulation distribution, relative strength index, as well as the relationship between the semi variance and day typical price , to analyze future returns on Prostatype Genomics.
Auto-correlation | -0.16 |
Insignificant reverse predictability
Prostatype Genomics AB has insignificant reverse predictability. Overlapping area represents the amount of predictability between Prostatype Genomics time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Prostatype Genomics price movement. The serial correlation of -0.16 indicates that over 16.0% of current Prostatype Genomics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.16 | |
| Spearman Rank Test | 0.07 | |
| Residual Average | 0.0 | |
| Price Variance | 0.37 |
Prostatype Genomics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Prostatype Genomics Technical Analysis
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Prostatype Genomics volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About Prostatype Genomics Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Prostatype Genomics AB on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Prostatype Genomics AB based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Prostatype Genomics price pattern first instead of the macroeconomic environment surrounding Prostatype Genomics. By analyzing Prostatype Genomics's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Prostatype Genomics's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Prostatype Genomics specific price patterns or momentum indicators. Please read more on our technical analysis page.
Prostatype Genomics February 2, 2026 Technical Indicators
Most technical analysis of Prostatype help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Prostatype from various momentum indicators to cycle indicators. When you analyze Prostatype charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1385 | |||
| Market Risk Adjusted Performance | (12.99) | |||
| Mean Deviation | 8.88 | |||
| Semi Deviation | 8.02 | |||
| Downside Deviation | 9.53 | |||
| Coefficient Of Variation | 560.81 | |||
| Standard Deviation | 14.2 | |||
| Variance | 201.78 | |||
| Information Ratio | 0.1752 | |||
| Jensen Alpha | 2.53 | |||
| Total Risk Alpha | 1.84 | |||
| Sortino Ratio | 0.261 | |||
| Treynor Ratio | (13.00) | |||
| Maximum Drawdown | 74.84 | |||
| Value At Risk | (10.71) | |||
| Potential Upside | 30.0 | |||
| Downside Variance | 90.87 | |||
| Semi Variance | 64.24 | |||
| Expected Short fall | (12.09) | |||
| Skewness | 1.66 | |||
| Kurtosis | 6.17 |
Prostatype Genomics February 2, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Prostatype stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.15 | ||
| Daily Balance Of Power | 0.13 | ||
| Rate Of Daily Change | 1.02 | ||
| Day Median Price | 1.98 | ||
| Day Typical Price | 1.96 | ||
| Price Action Indicator | (0.02) | ||
| Market Facilitation Index | 0.31 |
Complementary Tools for Prostatype Stock analysis
When running Prostatype Genomics' price analysis, check to measure Prostatype Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prostatype Genomics is operating at the current time. Most of Prostatype Genomics' value examination focuses on studying past and present price action to predict the probability of Prostatype Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prostatype Genomics' price. Additionally, you may evaluate how the addition of Prostatype Genomics to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |